Revvity Inc. (RVTY)

RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rig...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Confe...

Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compar...

Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Ch...

Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago.

Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP...